Variable | Training (131) | % | Validation (162) | P | ||
---|---|---|---|---|---|---|
Sex | 1 | 105 | 80.2 | 127 | 78.4 | 0.713 |
2 | 26 | 19.8 | 35 | 21.6 | ||
Age | Median | 48 | 47 | 0.611 | ||
Range | 21–80 | 15–73 | ||||
EBV | Undetectable | 54 | 41.2 | 37 | 22.8 | 0.003 |
< 1500 copies/ml | 53 | 40.5 | 91 | 56.2 | ||
> 1500 copies/ml | 24 | 18.3 | 34 | 21 | ||
Posttreatment EBV | Undetectable | 128 | 97.7 | 149 | 92 | 0.032 |
Detectable | 3 | 2.3 | 13 | 8 | ||
T | T1 | 13 | 9.9 | 11 | 6.8 | 0.582 |
T2 | 16 | 12.2 | 26 | 16 | ||
T3 | 73 | 55.7 | 85 | 52.5 | ||
T4 | 29 | 22.1 | 40 | 24.7 | ||
N | N0 | 12 | 9.2 | 5 | 3.1 | 0.008 |
N1 | 49 | 37.4 | 41 | 25.3 | ||
N2 | 47 | 35.7 | 80 | 49.4 | ||
N3 | 23 | 17.6 | 36 | 22.2 | ||
Stage | I | 1 | 0.8 | 2 | 1.2 | 0.243 |
II | 15 | 11.5 | 11 | 6.8 | ||
III | 72 | 55 | 80 | 49.4 | ||
IV | 43 | 32.8 | 69 | 42.6 |